Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues

Laboratory Investigation

Volumn 95, Issue 5, 2015, Pages 561-571

  Gündisch, Sibylle ^a   Annaratone, Laura ^b   Beese, Christian ^a   Drecol, Enken ^a   Marchiò, Caterina ^b,c   Quaglino, Elena ^d   Sapino, Anna ^b,c   Becker, Karl Friedrich ^a   Bussolati, Gianni ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B; TUMOR MARKER;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER THERAPY; CANCER TISSUE; COLD ISCHEMIA; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEEDLE BIOPSY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; TISSUE FIXATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CHEMISTRY; EXPERIMENTAL MAMMARY NEOPLASM; PROCEDURES; SPECIMEN HANDLING; TRANSGENIC MOUSE;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COLD ISCHEMIA; FEMALE; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SPECIMEN HANDLING; TISSUE FIXATION;

EID: 84929091332     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.37     Document Type: Article

References (46)

1. Hewitt SM, Badve SS, True LD. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy. Clin Cancer Res 2012;18:1524-1530.
2. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003;9(1 Pt 2):502S-510S.
3. Pinhel IF, Macneill FA, Hills MJ et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010;12:R76.
4. Betsou F, Barnes R, Burke T et al. Human biospecimen research: experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev 2009;18:1017-1025.
5. De Cecco L, Musella V, Veneroni S et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer 2009; 9:409.
6. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-e72.
7. Robb JA, Gulley ML, Fitzgibbons PL et al. A call to standardize preanalytic data elements for biospecimens. Arch Pathol Lab Med 2013;138: 526-537.
8. Juhl H. Preanalytical aspects: a neglected issue. Scand J Clin Lab Invest Suppl 2010;242:63-65.
9. Spruessel A, Steimann G, Jung M et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 2004;36:1030-1037.
10. Chafin D, Theiss A, Roberts E et al. Rapid two-temperature formalin fixation. PLoS One 2013;8:e54138.
11. Bussolati G, Annaratone L, Medico E et al. Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One 2011; 6:e21043.
12. Gundisch S, Hauck S, Sarioglu H et al. Variability of protein and phosphoprotein levels in clinical tissue specimens during the preanalytical phase. J Proteome Res 2012;11:5748-5762.
13. Gundisch S, Grundner-Culemann K, Wolff C et al. Delayed times to tissue fixation result in unpredictable global phosphoproteome changes. J Proteome Res 2013;12:4424-4434.
14. Baker AF, Dragovich T, Ihle NT et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005;11: 4338-4340.
15. Mueller C, Edmiston KH, Carpenter C et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011;6:e23780.
16. Bussolati G, Chiusa L, Cimino A et al. Tissue transfer to pathology labs: under vacuum is the safe alternative to formalin. Virchows Arch 2008;452:229-231.
17. Di Novi C, Minniti D, Barbaro S et al. Vacuum-based preservation of surgical specimens: an environmentally-safe step towards a formalinfree hospital. Sci Total Environ 2010;408:3092-3095.
18. Annaratone L, Marchio C, Russo R et al. A collection of primary tissue cultures of tumors from vacuum packed and cooled surgical specimens: a feasibility study. PLoS One 2013;8:e75193.
19. Comanescu M, Annaratone L, D'Armento G et al. Critical steps in tissue processing in histopathology. Recent Pat DNA Gene Seq 2012;6:22-32.
20. Neumeister VM, Parisi F, England AM et al. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Lab Invest 2014;94:467-474.
21. Becker KF, Taylor CR. 'Liquid morphology': Immunochemical analysis of proteins extracted from formalin-fixed paraffin-embedded tissues: Combining proteomics with immunohistochemistry. Appl Immunohistochem Mol Morphol 2011;19:1-9.
22. Porzia A, Lanzardo S, Citti A et al. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 2010;184:4170-4177.
23. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-198.
24. Quaglino E, Mastini C, Forni G et al. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008; Chapter 20:Unit 2091-20910.
25. Boggio K, Nicoletti G, Di Carlo E et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-596.
26. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
27. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795.
28. Wolff C, Schott C, Porschewski P et al. Successful protein extraction from over-fixed and long-term stored formalin-fixed tissues. PLoS One 2011;6:e16353.
29. Berg D, Hipp S, Malinowsky K et al. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer 2010;46:47-55.
30. Lips EH, Mulder L, de Ronde JJ et al. Neoadjuvant chemotherapy in ER+ HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012;131:827-836.
31. Moon YW, Park S, Sohn JH et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 2011; 137:1123-1130.
32. Anderson H, Hills M, Zabaglo L et al. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol 2011;22:1770-1776.
33. Tanei T, Shimomura A, Shimazu K et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011;37:155-161.
34. McAuliffe PF, Meric-Bernstam F, Mills GB et al. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010;10(Suppl 3):S59-S65.
35. Lin J, Sampath D, Nannini MA et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013;19:1760-1772.
36. Neumeister VM, Anagnostou V, Siddiqui S et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 2012;104: 1815-1824.
37. Bai Y, Cheng H, Bordeaux J et al. Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One 2013;8: e79901.
38. Berg D, Langer R, Tran K et al. Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues. Appl Immunohistochem Mol Morphol 2011;19:300-305.
39. Quaglino E, Rolla S, Iezzi M et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004;113:709-717.
40. Akbani R, Becker KF, Carragher N et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: The RPPA (Reverse Phase Protein Array) Society. Mol Cell Proteomics 2014;13:1625-1643.
41. Bonnas C, Specht K, Spleiss O et al. Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples. Int J Cancer 2012;131:1621-1632.
42. Meric-Bernstam F, Akcakanat A, Chen H et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res 2014;20:3870-3883.
43. Oakman C, Sapino A, Marchio C et al. Chemotherapy with or without trastuzumab. Ann Oncol 2010;21(Suppl 7):7112-7119.
44. Sapino A, Goia M, Recupero D et al. Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 2013;3:129.
45. Marchio C, Sapino A. The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr 2011;2011: 86-90.
46. Buesa RJ. Histology without formalin? Ann Diagn Pathol 2008;12: 387-396.